We are monitoring the impact of COVID-19 on Parkinson’s Disease Treatment Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 7138
Share on
Share on

Global Parkinson’s Disease Treatment Market Analysis - By Drug Class (Dopamine Receptor Antagonists, Mono Amine Oxidase Inhibitors, Carbidopa, Anticholinergics and Other Drug Classes), By Distribution Channel (Retailer Pharmacies, Hospital Pharmacies And Online Pharmacies), By Patient Care Setting (Clinics And Hospitals) and By Region - Industry Size, Share, Growth, Trends and Forecast | 2019 – 2024

Pulished: February, 2020
ID: 7138
Pages: 175

Global Parkinson’s Disease Treatment Market Size & Growth (2019 - 2024)

Globally, the size of the Parkinson’s Disease Treatment Market was worth USD 4.51 billion in 2019 and estimated to be growing at a CAGR of 5.97%, to reach USD 6.03 billion by 2024.

The slow development in stages of a neurological disorder that has features of the inexpressive face, the slowdown of spontaneous moments, walking with short steps, particular posture and muscle weakness which is caused by an area in the brain and also low production of the neurotransmitter dopamine, is often termed as Parkinson's disease.

The increasing older people across the world is acting as a primary growth factor for Parkinson disease. The increase in healthcare expenditure by the government in research and development is the factor that drives the growth of Parkinson's disease treatment market. The pharmacies which are available online are to grow faster during the forecast period. Robust health infrastructure and skilled neurologists professionals are the driving factors of hospitals, which propel the global Parkinson's disease treatment market.

Government authority or license, especially having the power to remove the others from making of expiry of branded drugs, along with the strong pipeline of products, is the opportunity provided during the forecast period.

Understanding of what causes complexity and diversity of Parkinson's disease is the main challenge for the investigators or the researchers. Investigators often work with local communities and caregivers to identify the problems of living with Parkinson's disease to translate scientific discoveries into patient care. The booklet named "Parkinson's Disease 2014: Advancing Research, Improving Lives" highlights the recent progress made in Parkinson's disease research and maps out the challenges and priorities. As the symptoms of the of PD progress, like walking, talking, swallowing, and completing other tasks which can become challenging.

Healthcare providers, individuals with Parkinson's disease, caretakers, and other stakeholders together to assist the state of Parkinson's disease, define the key or main challenges and set priorities for the advancing of Parkinsons Disease research. This can be challenging to get consent from the prodromal and early stage of Parkinson patients to give CSF samples for biomarker assessments in clinical trials.

Key happenings in this market in the recent past:

  • On June 13, 2019, Wockhardt got a booster from USFDA. The company has told that it has received a zero issue, after the inspection of bio-equivalence from the US health regulator.
  • October 14, 2019, Sun Pharma launched Cequa to treat dry eye disease in the US. The company has launched this ophthalmic solution called Cequa, used in the treatment of dry eyes in the US market. 
  • February 19, 2020, Sun Pharma proposed to set up a production unit in Pharma City. The founder and managing director Dilip Shanghvi of Sun Pharma told Times Of India that they are going to set up and manufacture the production company in Hyderabad.
  • On February 04, 2020, Sun Pharma launched severe nodular acne management capsules in the US. This is launched for patients who are below 12 years of age and older. This can be taken with or without food.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2018 – 2024

Base Year

2018

Forecast Period

2019 - 2024

Segments Covered

By Drug Type, Distribution Channel, Patient Care Setting and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

Teva (Israel), Novartis AG (Switzerland), GSK (UK), AbbVie (US), Merck (US), Boehringer Ingelheim (Germany), Impax Laboratories (US), Lundbeck (Denmark), Sun Pharma (India), Wockhardt (India), UCB (Belgium), Valeant Pharmaceuticals (Canada), and Acadia (US).

 

This research report on the Global Parkinson’s Disease Treatment Market segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2024.

Parkinson’s Disease Treatment Market Analysis – By Drug Class:

  • Dopamine Receptor Antagonists   
    • Pramipexole
    • Ropinirole
    • Apomorphine
    • Rotigotine
  • Mono Amine Oxidase Inhibitors    
    • Selegiline
    • Rasagiline
  • Carbidopa
  • Anticholinergics    
  • Other Drug Classes 

On the basis of drug class, the Carbidopa segment has the largest share in the segment.

Parkinson’s Disease Treatment Market Analysis – By Distribution Channel:

On the basis of the distribution channel, the hospital pharmacies segment has the largest share in the segment.

Parkinson’s Disease Treatment Market Analysis – By Patient Care Setting:

  • Clinics        
  • Hospitals  

By the patient care setting, the hospital's segment has the largest share.

Regional Analysis:

Europe has the leading market for Parkinson’s Disease Treatment in the world, which is followed by North America and the Asia Pacific regions. Asia Pacific region is expected to have the fastest growth rate during the forecast period, owing to the huge population base in the region.

List of key market participants leading the Global Parkinson’s Disease Treatment Market profiled in this report are:

  1. Teva (Israel)
  2. Novartis AG (Switzerland)
  3. GSK (UK)
  4. AbbVie (US)
  5. Merck (US)
  6. Boehringer Ingelheim (Germany)
  7. Impax Laboratories (US)
  8. Lundbeck (Denmark)
  9. Sun Pharma (India)
  10. Wockhardt (India)
  11. UCB (Belgium)
  12. Valeant Pharmaceuticals (Canada)
  13. Acadia (US)

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Class                   

                                5.1.1 Dopamine Receptor Antagonists   

                                                5.1.1.1 Pramipexole

                                                5.1.1.2 Ropinirole

                                                5.1.1.3 Apomorphine

                                                5.1.1.4 Rotigotine

                                5.1.2 Mono Amine Oxidase Inhibitors    

                                                5.1.2.1 Selegiline

                                                5.1.2.2 Rasagiline

                                5.1.3 Carbidopa

                                5.1.4 Anticholinergics    

                                5.1.5 Other Drug Classes              

                                5.1.6  Y-o-Y Growth Analysis, By Drug Class          

                                5.1.7  Market Attractiveness Analysis, By Drug Class        

                                5.1.8  Market Share Analysis, By Drug Class         

                5.2 Distribution Channel                               

                                5.2.1 Retailer Pharmacies            

                                5.2.2 Hospital Pharmacies            

                                5.2.3 Online Pharmacies               

                                5.2.4 Y-o-Y Growth Analysis, By Distribution Channel      

                                5.2.5 Market Attractiveness Analysis, By Distribution Channel    

                                5.2.6 Market Share Analysis, By Distribution Channel      

                5.3 Patient Care Setting                

                                5.3.1 Clinics        

                                5.3.2 Hospitals  

                                5.3.3 Y-o-Y Growth Analysis, By Patient Care Setting       

                                5.3.4  Market Attractiveness Analysis, By Patient Care Setting    

                                5.3.5  Market Share Analysis, By Patient Care Setting      

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Drug Class

                                                6.1.3.2 By Distribution Channel

                                                6.1.3.3 By Patient Care Setting

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Drug Class

                                                6.1.4.2 By Distribution Channel

                                                6.1.4.3 By Patient Care Setting

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Drug Class

                                                6.1.5.2 By Distribution Channel

                                                6.1.5.3 By Patient Care Setting

                6.2 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.3 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy            

                                6.2.6 France       

                6.4 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan         

                                6.3.5 Australia   

                                6.3.6 South Korea           

                6.5 Latin America                             

                                6.4.1 Introduction           

                                6.4.2 Brazil          

                                6.4.3 Argentina

                                6.4.4 Mexico     

                                6.4.5 Rest of Latin America          

                6.6 Middle East & Africa                               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa         

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Teva                              

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Novartis AG                                

                8.3 GSK                                

                8.4 AbbVie                         

                8.5 Merck                           

                8.6 Boehringer Ingelheim                            

                8.7 Impax Laboratories                 

                8.8 Lundbeck                    

                8.9 Sun Pharma                                

                8.10 Wockhardt                               

                8.11 UCB                             

                8.12 Valeant Pharmaceuticals                    

                8.13 Acadia                        

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities                                         

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Global and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms by drug along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Parkinson’s Disease Treatment Market By Region, From 2019-2024( USD Million )
  2. Global Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  3. Global Dopamine Receptor Antagonists Market By Region, From 2019-2024( USD Million )
  4. Global Mono Amine Oxidase Inhibitors Market By Region, From 2019-2024( USD Million )
  5. Global Carbidopa Market By Region, From 2019-2024( USD Million )
  6. Global Anticholinergics  Market By Region, From 2019-2024( USD Million )
  7. Global Other Drug Classes Market By Region, From 2019-2024( USD Million )
  8. Global Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  9. Global Retailer Pharmacies Market By Region, From 2019-2024( USD Million )
  10. Global Hospital Pharmacies  Market By Region, From 2019-2024( USD Million )
  11. Global Online Pharmacies Market By Region, From 2019-2024( USD Million )
  12. Global Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  13. Global Clinics  Market By Region, From 2019-2024( USD Million )
  14. Global Hospitals Market By Region, From 2019-2024( USD Million )
  15. North America Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  16. North America Dopamine Receptor Antagonists Market By Region, From 2019-2024( USD Million )
  17. North America Mono Amine Oxidase Inhibitors Market By Region, From 2019-2024( USD Million )
  18. North America Carbidopa Market By Region, From 2019-2024( USD Million )
  19. North America Anticholinergics  Market By Region, From 2019-2024( USD Million )
  20. North America Other Drug Classes Market By Region, From 2019-2024( USD Million )
  21. North America Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  22. North America Retailer Pharmacies Market By Region, From 2019-2024( USD Million )
  23. North America Hospital Pharmacies  Market By Region, From 2019-2024( USD Million )
  24. North America Online Pharmacies Market By Region, From 2019-2024( USD Million )
  25. North America Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  26. North America Clinics  Market By Region, From 2019-2024( USD Million )
  27. North America Hospitals Market By Region, From 2019-2024( USD Million )
  28. United States Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  29. United States Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  30. United States Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  31. Canada Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  32. Canada Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  33. Canada Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  34. Europe Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  35. Europe Dopamine Receptor Antagonists Market By Region, From 2019-2024( USD Million )
  36. Europe Mono Amine Oxidase Inhibitors Market By Region, From 2019-2024( USD Million )
  37. Europe Carbidopa Market By Region, From 2019-2024( USD Million )
  38. Europe Anticholinergics  Market By Region, From 2019-2024( USD Million )
  39. Europe Other Drug Classes Market By Region, From 2019-2024( USD Million )
  40. Europe Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  41. Europe Retailer Pharmacies Market By Region, From 2019-2024( USD Million )
  42. Europe Hospital Pharmacies  Market By Region, From 2019-2024( USD Million )
  43. Europe Online Pharmacies Market By Region, From 2019-2024( USD Million )
  44. Europe Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  45. Europe Clinics  Market By Region, From 2019-2024( USD Million )
  46. Europe Hospitals Market By Region, From 2019-2024( USD Million )
  47. U.K. Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  48. U.K. Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  49. U.K. Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  50. Germany Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  51. Germany Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  52. Germany Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  53. France Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  54. France Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  55. France Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  56. Italy Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  57. Italy Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  58. Italy Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  59. Spain Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  60. Spain Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  61. Spain Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  62. Asia Pacific Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  63. Asia Pacific Dopamine Receptor Antagonists Market By Region, From 2019-2024( USD Million )
  64. Asia Pacific Mono Amine Oxidase Inhibitors Market By Region, From 2019-2024( USD Million )
  65. Asia Pacific Carbidopa Market By Region, From 2019-2024( USD Million )
  66. Asia Pacific Anticholinergics  Market By Region, From 2019-2024( USD Million )
  67. Asia Pacific Other Drug Classes Market By Region, From 2019-2024( USD Million )
  68. Asia Pacific Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  69. Asia Pacific Retailer Pharmacies Market By Region, From 2019-2024( USD Million )
  70. Asia Pacific Hospital Pharmacies  Market By Region, From 2019-2024( USD Million )
  71. Asia Pacific Online Pharmacies Market By Region, From 2019-2024( USD Million )
  72. Asia Pacific Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  73. Asia Pacific Clinics  Market By Region, From 2019-2024( USD Million )
  74. Asia Pacific Hospitals Market By Region, From 2019-2024( USD Million )
  75. Japan Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  76. Japan Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  77. Japan Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  78. China Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  79. China Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  80. China Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  81. India Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  82. India Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  83. India Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  84. Australia Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  85. Australia Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  86. Australia Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  87. South Korea Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  88. South Korea Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  89. South Korea Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  90. Latin America Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  91. Latin America Dopamine Receptor Antagonists Market By Region, From 2019-2024( USD Million )
  92. Latin America Mono Amine Oxidase Inhibitors Market By Region, From 2019-2024( USD Million )
  93. Latin America Carbidopa Market By Region, From 2019-2024( USD Million )
  94. Latin America Anticholinergics  Market By Region, From 2019-2024( USD Million )
  95. Latin America Other Drug Classes Market By Region, From 2019-2024( USD Million )
  96. Latin America Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  97. Latin America Retailer Pharmacies Market By Region, From 2019-2024( USD Million )
  98. Latin America Hospital Pharmacies  Market By Region, From 2019-2024( USD Million )
  99. Latin America Online Pharmacies Market By Region, From 2019-2024( USD Million )
  100. Latin America Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  101. Latin America Clinics  Market By Region, From 2019-2024( USD Million )
  102. Latin America Hospitals Market By Region, From 2019-2024( USD Million )
  103. Brazil Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  104. Brazil Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  105. Brazil Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  106. Argentina Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  107. Argentina Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  108. Argentina Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  109. Mexico Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  110. Mexico Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  111. Mexico Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  112. Rest of Latin America Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  113. Rest of Latin America Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  114. Rest of Latin America Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  115. Middle East and Africa Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  116. Middle East and Africa Dopamine Receptor Antagonists Market By Region, From 2019-2024( USD Million )
  117. Middle East and Africa Mono Amine Oxidase Inhibitors Market By Region, From 2019-2024( USD Million )
  118. Middle East and Africa Carbidopa Market By Region, From 2019-2024( USD Million )
  119. Middle East and Africa Anticholinergics  Market By Region, From 2019-2024( USD Million )
  120. Middle East and Africa Other Drug Classes Market By Region, From 2019-2024( USD Million )
  121. Middle East and Africa Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  122. Middle East and Africa Retailer Pharmacies Market By Region, From 2019-2024( USD Million )
  123. Middle East and Africa Hospital Pharmacies  Market By Region, From 2019-2024( USD Million )
  124. Middle East and Africa Online Pharmacies Market By Region, From 2019-2024( USD Million )
  125. Middle East and Africa Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  126. Middle East and Africa Clinics  Market By Region, From 2019-2024( USD Million )
  127. Middle East and Africa Hospitals Market By Region, From 2019-2024( USD Million )
  128. Middle East Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  129. Middle East Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  130. Middle East Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )
  131. Africa Parkinson’s Disease Treatment Market By Drug Class , From 2019-2024( USD Million )
  132. Africa Parkinson’s Disease Treatment Market By Distribution Channel , From 2019-2024( USD Million )
  133. Africa Parkinson’s Disease Treatment Market By Patient Care Setting, From 2019-2024( USD Million )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample